NUMI.TO Numinus Wellness (TSX) C$0.05 close Apr 08 2026: earnings to watch

The NUMI.TO stock closed at C$0.05 on Apr 08 2026 as the market closed ahead of an earnings release scheduled for Apr 09 2026. Traders showed heavy interest with 989,752 shares traded and relative volume of 5.37. Numinus Wellness Inc. (NUMI.TO) reports tomorrow, and investors will focus on cash runway, patient volumes and revenue trends. This earnings spotlight summarizes the key metrics, valuation, and what could move the stock at the TSX close.

NUMI.TO stock: earnings timing and market context

Numinus Wellness (NUMI.TO) will announce results on 2026-04-09. The company listed the earnings announcement for the morning of Apr 9. Market participants will compare reported EPS to the trailing EPS of -0.08 and judge guidance.

Today’s close at C$0.05 matched the prior close. Year range sits between C$0.03 and C$0.13. With 320,551,620 shares outstanding, the market cap is roughly C$16,027,581.00.

NUMI.TO stock valuation and key ratios

Valuation metrics show a mixed picture. Price to sales is 3.01, EV to sales is 3.29, and trailing PE is negative at -1.33. Cash per share is C$0.00 (rounded C$0.0028), while book value per share is negative.

Working capital and liquidity are tight. Current ratio is 0.61 and operating cash flow per share is -0.01. These ratios reflect ongoing cash burn and the need for clear cash-flow improvements in the report.

NUMI.TO stock: operational drivers and risks

Numinus runs two divisions. Salvation Botanicals handles lab services and cultivation. Numinus Health operates clinics, training and supportive therapies. Revenues stem from patient services, lab testing, and practitioner training.

Key risks include regulatory shifts in psychedelic policy, capital access and slow margin recovery. Payroll and facility costs remain material given about 2,000 full time employees.

NUMI.TO stock: price action and technicals

The stock closed at C$0.05 with intraday range C$0.05–C$0.05. Short-term momentum shows improvement. Price averages: 50-day C$0.0465 and 200-day C$0.0438.

Performance reads: 3‑month +42.86%, 6‑month +66.67%, year-to-date +25.00%, and one-year -50.00%. Average volume is 184,378; today’s volume spiked to 989,752, signaling elevated interest into earnings.

Meyka AI grade and NUMI.TO stock forecast

Meyka AI rates NUMI.TO with a score of 65.98 out of 100: Grade B and suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 12‑month base price of C$0.07 versus the current C$0.05, implying an upside of +40.00%. Conservative target: C$0.03 (‑40.00%). Bull target: C$0.12 (+140.00%). Forecasts are model-based projections and not guarantees.

Earnings watchlist for NUMI.TO stock

Investors should watch revenue, adjusted EBITDA, and patient visit counts. Management commentary on cash runway and capital needs will matter most.

Also monitor margins at Salvation Botanicals and clinic utilization at Numinus Health. Any updated guidance or timing for breakeven will affect the TSX reaction.

Final Thoughts

Numinus (NUMI.TO) enters earnings with a low share price and high scrutiny. The stock closed at C$0.05 on Apr 08 2026 and trade volume spiked to 989,752 shares. Key focus areas are revenue growth, cash flow improvement, and any guidance on achieving positive operating margins. Meyka AI’s forecast model projects a 12‑month base price of C$0.07, an implied +40.00% upside versus the current price. Our grade, 65.98 / 100 (B, HOLD), reflects weak liquidity metrics, negative operating cash flow per share of -0.01, and sector headwinds in Healthcare. Short‑term traders may react to earnings beats or misses. Long‑term investors should require clearer evidence of margin recovery and cash stability before increasing exposure. For the latest updates, see our Meyka AI market page for NUMI.TO and follow the earnings release closely source and peer comparisons source. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.